IONS News and Press, Ionis Pharmaceuticals Inc. From 02/20/24

2024-02-20 21:29:31 ET Summary Tweedy Browne's 13F portfolio value increased from $1.87B to $2.05B this quarter. The largest position in the portfolio is Berkshire Hathaway at ~21%. Stake increases include FMC Corporation, U-Haul Holding, and Sealed Air, while stake decreases ...

2024-02-20 11:18:12 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis receives FDA orphan drug status for familial chylomicronemia drug Ionis-AstraZeneca amyloid cardiomyopathy candidate gets FDA fast track designation ...

2024-02-15 07:20:49 ET Read the full article on Seeking Alpha For further details see: Ionis receives FDA orphan drug status for familial chylomicronemia drug

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome PR Newswire CARLSBAD, Calif. , Feb. 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administrat...

2024-02-14 21:40:00 ET Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, ...

2024-02-08 08:35:27 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis angioedema drug shows positive results in Phase 3 trial FDA approves AstraZeneca, Ionis drug for ATTRv-PN Seeking Alpha’s Quant Rating on Io...

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy PR Newswire CARLSBAD, Calif. , Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and D...

Ionis to hold fourth quarter and full year 2023 financial results webcast PR Newswire Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq:...

2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...

2024-01-22 14:00:02 ET William Blair analyst issues OUTPERFORM recommendation for IONS on January 22, 2024 02:35PM ET. The previous analyst recommendation was Outperform. IONS was trading at $51.455 at issue of the analyst recommendation. The overall analyst consensus : ...